A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell Carcinoma

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This study is a multicenter, prospective, single-arm Phase II clinical trial evaluating the efficacy and safety of neoadjuvant therapy with TROP-2 ADC in combination with toripalimab for resectable locally advanced oral squamous cell carcinoma, followed by curative surgery and postoperative adjuvant radiotherapy or chemoradiotherapy.
Epistemonikos ID: e249df92b022e001e449ae67088bb1cfb405d0cb
First added on: Aug 21, 2026